Cost-effectiveness of Antiviral Stockpiling and Near-Patient Testing for Potential Influenza Pandemic

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Siddiqui, M. Ruby ; Edmunds, W. John
• Description:
  A decision analytical model was developed to investigate the cost-effectiveness of stockpiling antiviral (AV) drugs for a potential influenza pandemic in the United Kingdom and the possible role of near-patient testing in conserving AV drug stocks. Under base-case assumptions (including a fixed stockpile that was smaller than the clinical attack rate), the treat-only option (treating all symptomatic patients with AV drugs) would be considered cost-effective ( pound1,900- pound13,700 per quality-adjusted life year [QALY] gained, depending on the fatality scenario), compared with no intervention (nonintervention but management of cases as they arise). The test-treat option (testing all symptomatic patients but treating those with positive tests results only) would result in moderate gains in QALYs over the treat-only option but at relatively large additional costs. Stockpiling sufficient AV drugs (but not near-patient tests) to treat all patients with clinical cases would be cost-effective, provided AV drugs are effective at preventing deaths from pandemic influenza.
• Subjects:
  Antiviral Agents Cost-Benefit Analysis Decision Support Techniques Disease Outbreaks Health Care Costs Humans Influenza, Human Quality-Adjusted Life Years Sensitivity And Specificity
• Source:
  Emerg Infect Dis. 14(2):267-274.
• Document Type:
  Journal Article
• Volume:
  14
• Issue:
  2
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:c13f726346765af1ae914243d66a4b1aa3d78eddb43c474bdcebd6ab1c82265a
• Download URL:
  https://stacks.cdc.gov/view/cdc/16819/cdc_16819_DS1.pdf
• File Type:
  [PDF - 424.29 KB ]